Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Addex Therapeutics Ltd., a foreign private issuer based in Geneva, Switzerland, for the month of October 2023. The filing, dated October 20, 2023, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1) into the company's registration statements on Form F-3 and Form S-8.
Financial Metrics
The filing text does not provide specific financial data. No revenue, profit, cash flow, margins, debt, or liquidity figures are disclosed within this document. The filing acts solely as a conduit for the referenced press release.
Material Changes
The filing text does not contain information regarding material changes versus prior periods. Any such updates would be contained within the attached press release (Exhibit 99.1), the content of which is not included in the provided source text.
Guidance, Outlook, and Risks
Management commentary, future guidance, risk factors, contingencies, and unusual items are not detailed in this filing. The document references a press release for these details but does not reproduce the text of that release.
Key Facts for Investor Verification
- Verify the content of the press release dated October 20, 2023 (Exhibit 99.1), as this filing incorporates it by reference without summarizing its substance.
- Confirm the specific corporate or clinical developments announced in the referenced press release, as no such details appear in the Form 6-K text itself.
- Note that this filing updates registration statements (Form F-3 No. 333-255089 and Form S-8 Nos. 333-255124 and 333-272515) with the new information.